205 related articles for article (PubMed ID: 35753383)
21. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
[TBL] [Abstract][Full Text] [Related]
22. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
[TBL] [Abstract][Full Text] [Related]
23. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
Singh S; Dulai PS; Vande Casteele N; Battat R; Fumery M; Boland BS; Sandborn WJ
Aliment Pharmacol Ther; 2019 Oct; 50(8):848-857. PubMed ID: 31483522
[TBL] [Abstract][Full Text] [Related]
24. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
[TBL] [Abstract][Full Text] [Related]
25. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
26. Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab.
Porth R; Deyhim T; Zullow S; Rabinowitz LG; Grossberg LB; Roblin X; Paul S; Cheifetz AS; Papamichael K
Inflamm Bowel Dis; 2024 Jul; ():. PubMed ID: 38953651
[TBL] [Abstract][Full Text] [Related]
27. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring.
Albader F; Golovics PA; Gonczi L; Bessissow T; Afif W; Lakatos PL
World J Gastroenterol; 2021 Oct; 27(37):6231-6247. PubMed ID: 34712029
[TBL] [Abstract][Full Text] [Related]
29. Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease.
Ma C; Battat R; Jairath V; Vande Casteele N
Curr Treat Options Gastroenterol; 2019 Mar; 17(1):127-145. PubMed ID: 30680599
[TBL] [Abstract][Full Text] [Related]
30. Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease.
Lyles JL; Mulgund AA; Bauman LE; Su W; Fei L; Chona DL; Sharma P; Etter RK; Hellmann J; Denson LA; Minar P; Dykes DM; Rosen MJ
Inflamm Bowel Dis; 2021 Mar; 27(4):482-492. PubMed ID: 32448898
[TBL] [Abstract][Full Text] [Related]
31. Fecal transplantation for treatment of inflammatory bowel disease.
Imdad A; Nicholson MR; Tanner-Smith EE; Zackular JP; Gomez-Duarte OG; Beaulieu DB; Acra S
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012774. PubMed ID: 30480772
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
Mitrev N; Leong RW
Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
[TBL] [Abstract][Full Text] [Related]
33. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
Hoseyni H; Xu Y; Zhou H
J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
[TBL] [Abstract][Full Text] [Related]
35. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
36. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
Papamichael K; Stocco G; Ruiz Del Agua A
Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
[TBL] [Abstract][Full Text] [Related]
37. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
Sinopoulou V; Gordon M; Akobeng AK; Gasparetto M; Sammaan M; Vasiliou J; Dovey TM
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013531. PubMed ID: 34844288
[TBL] [Abstract][Full Text] [Related]
38. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
Cheifetz AS; Abreu MT; Afif W; Cross RK; Dubinsky MC; Loftus EV; Osterman MT; Saroufim A; Siegel CA; Yarur AJ; Melmed GY; Papamichael K
Am J Gastroenterol; 2021 Oct; 116(10):2014-2025. PubMed ID: 34388143
[TBL] [Abstract][Full Text] [Related]
39. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
Samaan MA; Arkir Z; Ahmad T; Irving PM
Expert Opin Biol Ther; 2018 Dec; 18(12):1271-1279. PubMed ID: 30339466
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
Dutt K; Vasudevan A
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
